PRCT
Procept Biorobotics Corp
17.50$
-3.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
Procept Biorobotics Corp (PRCT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -57 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -12 | -11 | -13 | -15 | -13 | -13 | -16 | -18 | -17 | -20 | -25 | -36 | -28 | -19 | -25 | -32 | -16 | -19 | -32 | -17 | -15 | -6.6 | -10 | -38 | -57 | -112 | |
| 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 0.9 | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | 0.7 | 0.8 | 0.6 | 1.1 | 1.3 | 1.2 | 1.3 | 1.3 | 1.5 | 1.5 | 1.6 | 1.6 | 1.7 | 1.7 | 3.7 | 8.8 | |
| 0.5 | 0.5 | 0.6 | 0.6 | 0.7 | 0.7 | 0.9 | 1.5 | 1.6 | 2.7 | 3.2 | 2.9 | 3.7 | 5.1 | 5.3 | 5.0 | 6.3 | 8.0 | 8.5 | 9.1 | 10 | 12 | 14 | 11 | 13 | 28 | 66 | |
| – | – | 0.2 | 0.7 | 0.3 | 0.9 | 0.6 | 1.5 | 1.6 | 2.7 | 3.3 | 7.1 | 4.0 | 5.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.2 | 0.2 | 0.2 | -0.1 | -3.6 | -0.6 | -0.1 | -0.4 | -3.3 | -1.3 | -2.1 | -4.8 | -13 | -8.8 | -1.1 | -3.5 | -14 | -0.2 | -8.5 | -25 | -4.3 | -9.5 | -2.0 | 8.0 | -22 | -32 | -48 | |
| 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.3 | 0.1 | 0.2 | 1.5 | 0.9 | 5.3 | 5.4 | 5.8 | 8.7 | 1.9 | 1.0 | 0.2 | 1.2 | 1.8 | 2.8 | 2.9 | 1.9 | 2.9 | 5.9 | 13 | |
| -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | -0.3 | -0.1 | -0.2 | -1.5 | -0.9 | -5.3 | -5.4 | -5.8 | -8.7 | -1.9 | -1.0 | -0.2 | -1.2 | -1.8 | -2.8 | -2.9 | -1.9 | -2.9 | -5.9 | -13 | |
| – | – | – | – | – | – | – | – | 1.3 | 2.9 | 0.8 | 2.4 | 0.4 | 2.4 | – | 3.6 | – | – | 2.1 | – | – | – | 3.5 | -0.6 | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | 1.2 | 1.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 14 | 14 | 79 | 0.2 | 1.2 | 86 | 174 | 0.6 | 1.3 | 2.9 | 0.8 | -1.3 | 0.4 | 2.4 | 162 | 2.9 | 2.6 | 5.3 | 1.7 | 171 | 1.3 | 4.4 | 1.1 | 4.4 | 0.2 | 4.7 | 10 | |
| 1.6 | 46 | 68 | -13 | -14 | 73 | 161 | -16 | -17 | -14 | -21 | -27 | -41 | -31 | 137 | -31 | -32 | -11 | -17 | 137 | -18 | -13 | -8.4 | -7.8 | -41 | -59 | -116 | |
| -12 | -12 | -11 | -13 | -15 | -13 | -13 | -17 | -18 | -17 | -21 | -26 | -41 | -34 | -25 | -34 | -34 | -17 | -19 | -34 | -19 | -18 | -9.5 | -12 | -41 | -63 | -126 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.